MARKET

AGTC

AGTC

Applied Genetic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8389
-0.0009
-0.11%
Closed 18:49 05/25 EDT
OPEN
0.8400
PREV CLOSE
0.8398
HIGH
0.8649
LOW
0.8100
VOLUME
107.35K
TURNOVER
--
52 WEEK HIGH
4.650
52 WEEK LOW
0.5820
MARKET CAP
42.56M
P/E (TTM)
-0.5755
1D
5D
1M
3M
1Y
5Y
AGTC to Present at the H.C. Wainwright Global Investment Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the...
GlobeNewswire · 05/18 12:00
Chardan Research Adjusts Price Target for Applied Genetic Technologies to $5 From $8, Maintains Buy Rating
MT Newswires · 05/18 10:49
AGTC Announces Three-Month Interim Results From Skyline Trial Of AGTC-501 For The Treatment Of X-Linked Retinitis Pigmentosa
– 62.5% of Patients in Dose Group B Were Responders for Improvements in Visual Sensitivity, the Study’s Primary Efficacy Endpoint – – Continued Strong Safety Data – – Robust Safety
Benzinga · 05/16 20:16
AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa
– 62.5% of Patients in Dose Group B Were Responders for Improvements in Visual Sensitivity, the Study’s Primary Efficacy Endpoint – – Continued Strong Safety Data – – Robust Safety and Efficacy Data Consistent with Previously Reported Results from the Phas...
GlobeNewswire · 05/16 20:01
Applied Genetic Technologies Sees 'Positive' Interim Data From Trial of AGTC-501 to Treat Retinitis Pigmentosa; Shares Rise
MT Newswires · 05/16 16:30
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
AGTC Hosts Topping Off Ceremony for Gene Therapy Manufacturing Facility to Celebrate the Building’s Structural Completion
– Facility in Alachua, Florida Is Expected to be Completed in the Fourth Quarter of 2022 – GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology comp...
GlobeNewswire · 05/10 12:00
Applied Genetic Technologies Announces 18-Month Data From Ongoing Phase 1/2 Clinical Study Of AGTC-501 Presented At The Association For Research In Vision And Ophthalmology 2022 Annual Meeting
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and
Benzinga · 05/04 12:09
More
No Data
Learn about the latest financial forecast of AGTC. Analyze the recent business situations of Applied Genetic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

37.50%Strong Buy
62.50%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AGTC stock price target is 13.63 with a high estimate of 35.00 and a low estimate of 5.00.
High35.00
Average13.63
Low5.00
Current 0.8389
EPS
Actual
Estimate
-0.36-0.27-0.18-0.09
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 84
Institutional Holdings: 16.23M
% Owned: 31.99%
Shares Outstanding: 50.73M
TypeInstitutionsShares
Increased
15
857.75K
New
9
3.80M
Decreased
14
798.01K
Sold Out
11
558.42K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.55%
Pharmaceuticals & Medical Research
+0.02%
Key Executives
Non-Executive Chairman/Independent Director
Scott Koenig
President/Chief Executive Officer/Director
Susan Washer
Chief Financial Officer
Jonathan Lieber
Chief Scientific Officer
Abraham Scaria
Vice President
Sarah Disalvatore
General Counsel
Hope D'oyley-gay
Other
Stephen Potter
Other
Susan Schneider
Independent Director
William Aliski
Independent Director
Yehia Hashad
Independent Director
Edward Hurwitz
Independent Director
Ivana Magovcevic-Liebisch
Independent Director
James Robinson
Independent Director
James Rosen
Independent Director
Anne Vanlent
No Data
No Data
About AGTC
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is in the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM) and a optogenetics program, as well as a preclinical program in dry age-related macular degeneration (dAMD). It has approximately one preclinical program in otology and two preclinical programs targeting central nervous system disorders (CN), including frontotemporal dementia and amyotrophic lateral sclerosis. Its optogenetics program is being developed in collaboration with Bionic Sight, LLC and its otology program is being developed in collaboration with Otonomy, Inc. In addition to its product pipeline, the Company has also developed broad technological and manufacturing capabilities in synthetic promoter development and optimization.

Webull offers kinds of Applied Genetic Technologies Corp stock information, including NASDAQ:AGTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGTC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGTC stock methods without spending real money on the virtual paper trading platform.